Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain

Condition(s) studied

Investigational drug(s) / intervention(s)

Triamcinolone Acetonide: 1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain

Bupivacaine Hydrochloride: 20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain

Dexmedetomidine: Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline

Study summary

Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.

Eligibility

Primary outcome measure(s)

• Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection. — 7 months
  Value of intra-articular Injection in Pain Reduction of chronic knee pain manifested by recurrence of pain.

Trial sites (1)

More Tanta University trials in Egypt